Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sanjeeva Herath has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Functional and Structural Renoprotection After Experimental Acute Kidney Injury in Subclinical Chronic Kidney Disease In Vivo

    by Sanjeeva Herath, Amy Y. M. Au, Kylie M. Taylor, Natasha Kapoor-Kaushik, Zoltán H. Endre, Jonathan H. Erlich

    Subclinical chronic kidney disease (sCKD) predisposes one to acute kidney injury (AKI) and chronic kidney disease (CKD). Reduced kidney functional reserve (KFR) detects sCKD in preclinical studies and predicts AKI after cardiac surgery. We evaluated renal protection in a rat model of kidney injury where ischaemia–reperfusion injury (IRI) was induced after sCKD. Dual treatment boosting nicotinamide adenine dinucleotide (NAD) by nicotinamide riboside (NR) combined with the mitochondria-targeted antioxidant SkQR1 protected the KFR and reduced structural kidney damage, including markers of vascular integrity and the relative blood volume (rBV). The dual treatment upregulated Sirt1 and Nrf2, increased the nuclear localisation of the mitochondrial biogenesis regulator PGC-1α and the mitochondrial protein marker COX4, and upregulated the antioxidant gene NOQ1. These observations suggest mitochondrial protection and modulation of the cellular redox state provided long-term structural and functional protection against kidney injury superimposed on background sCKD.


  • Kidney functional reserve and damage biomarkers in subclinical chronic kidney disease and acute kidney injury

    by Kylie M. Taylor, Amy Y. M. Au, Sanjeeva Herath, Lena Succar, Jasmine Wong, Jonathan H. Erlich, Zoltán H. Endre

    Early kidney function loss is poorly identified by serum creatinine (sCr)-based measurements. Direct kidney functional reserve (KFR) measurement before kidney injury and elevated urinary biomarkers clusterin and kidney injury molecule-1 detect subclinical chronic kidney disease (sCKD) after kidney injury despite normal range sCr and creatinine clearance. Reliance on sCr masks underlying sCKD. Acute kidney injury risk evaluation requires direct glomerular filtration rate measurement and KFR, whereas kidney damage biomarkers facilitate identification of prior subclinical injury.


  • Open Access

    WCN23-0928 URINARY AND PLASMA BIOMARKER PANEL FOR EARLY DETECTION OF ACUTE KIDNEY INJURY (AKI) AND PROGNOSTIC STRATIFICATION

    by S. Herath, J. Erlich, A. Au, D. Murphy, M. David, K. Taylor, Z. Endre

  • Open Access

    Electronic alerts and a care bundle for acute kidney injury—an Australian cohort study

    by Sradha Kotwal, Sanjeeva Herath, Jonathan Erlich, Sally Boardman, Jennifer Qian, Paul Lawton, Craig Campbell, Andrew Whatnall, Su Teo, A Rita Horvath, et al.

    Background: Early recognition of hospital-acquired acute kidney injury (AKI) may improve patient management and outcomes.Methods: This multicentre study was conducted at three hospitals (H1—intervention; H2 and H3—controls) served by a single laboratory. The intervention bundle [an interruptive automated alerts (aAlerts) showing AKI stage and baseline creatinine in the eMR, a management guide and junior medical staff education] was implemented only at H1. Outcome variables included length-of-stay (LOS), all-cause in-hospital mortality and management quality.Results: Over 6 months, 639 patients developed AKI (265 at H1 and 374 at controls), with 94.7% in general wards; 537 (84%) patients developed Stage 1, 58 (9%) Stage 2 and 43 (7%) Stage 3 AKI. Median LOS was 9 days (IQR 4–17) and was not different between intervention and controls. However, patients with AKI stage 1 had shorter LOS at H1 [median 8 versus 10 days (P = 0.021)]. Serum creatinine had risen prior to admission in most patients. Documentation of AKI was better in H1 (94.8% versus 83.4%; P = 0.001), with higher rates of nephrology consultation (25% versus 19%; P = 0.04) and cessation of nephrotoxins (25.3 versus 18.8%; P = 0.045). There was no difference in mortality between H1 versus controls (11.7% versus 13.0%; P = 0.71).Conclusions: Most hospitalized patients developed Stage 1 AKI and developed AKI in the community and remained outside the intensive care unit (ICU). The AKI eAlert bundle reduced LOS in most patients with AKI and increased AKI documentation, nephrology consultation rate and cessation of nephrotoxic medications.


  • Open Access

    Biomarker Rule-in or Rule-out in Patients With Acute Diseases for Validation of Acute Kidney Injury in the Emergency Department (BRAVA): A Multicenter Study Evaluating Urinary TIMP-2/IGFBP7

    by Hyun Suk Yang, Mina Hur, Kyeong Ryong Lee, Hanah Kim, Hahn Young Kim, Jong Won Kim, Mui Teng Chua, Win Sen Kuan, Horng Ruey Chua, Chagriya Kitiyakara, et al.

    Hyun Suk Yang, M.D., Ph.D., Mina Hur, M.D., Ph.D., Kyeong Ryong Lee, M.D., Ph.D., Hanah Kim, M.D., Ph.D., Hahn Young Kim, M.D., Ph.D., Jong Won Kim, M.D., Ph.D., Mui Teng Chua, M.D., Win Sen Kuan, M.D., Horng Ruey Chua, M.D., Chagriya Kitiyakara, M.D., Phatthranit Phattharapornjaroen, M.D., Anchalee Chittamma, Ph.D., Thiyapha Werayachankul, M.Sc., Urmila Anandh, M.D., Sanjeeva Herath, M.B., Ch.B., Zoltan Endre, M.D., Ph.D., Andrea Rita Horvath, M.D., Ph.D., Paola Antonini, M.D., and Salvatore Di Somma, M.D., Ph.D. on behalf of the GREAT Network. Ann Lab Med 2022;42:178-87. https://doi.org/10.3343/alm.2022.42.2.178


  • The kinetic estimated glomerular filtration rate ratio predicts acute kidney injury

    by Daniel Christiadi, Jonathan Erlich, Melissa Levy, Sanjeeva Herath, Jennifer Qian, Sally Boardman, Craig Campbell, Sradha Kotwal, Andrea R. Horvath, Zoltán Endre

    Aim: Kinetic estimated Glomerular Filtration Rate (KeGFR) approximates GFR under non‐steady‐state conditions. We investigated whether the ratio of KeGFR difference to baseline eGFR could predict acute kidney injury (AKI) earlier than a creatinine‐based algorithm that triggered an AKI electronic Alert (eAlert).Methods: This retrospective, single‐centre, proof‐of‐concept cohort study assessed all patients diagnosed with AKI by an automated serum creatinine‐based eAlert. The kinetic eGFR, the kinetic eGFR difference from baseline and the ratio of difference to baseline was calculated in subjects with at least two serum creatinine (sCr) measurements within 72 h of AKI.Results: Patients in the AKI cohort (n = 140) had a significant decline in KeGFR ratio (AKI: 17% IQR 7% to 29%, Non‐AKI: 0 IQR −12% to 9%; P‐value <.0001). A decrease of the ratio greater than 10% predicted AKI with a sensitivity of 66%, a specificity of 77%, a positive predictive value of 63%, and negative predictive value of 80%. The median lead time between KeGFR ratio decrease and AKI was 24 h (IQR: 19–27 h).Conclusions: KeGFR ratio is a cheap, simple method that predicted AKI 24 h before laboratory detection. KeGFR may facilitate triaging patients to increased monitoring or intervention.


  • Open Access

    Selection and validation of reference genes for normalisation of gene expression in ischaemic and toxicological studies in kidney disease

    by Sanjeeva Herath, Hongying Dai, Jonathan Erlich, Amy Ym Au, Kylie Taylor, Lena Succar, Zoltán H Endre

    Normalisation to standard reference gene(s) is essential for quantitative real-time polymerase chain reaction (RT-qPCR) to obtain reproducible and comparable results of a gene of interest (GOI) between subjects and under varying experimental conditions. There is limited evidence to support selection of the commonly used reference genes in rat ischaemic and toxicological kidney models. Employing these models, we determined the most stable reference genes by comparing 4 standard methods (NormFinder, qBase+, BestKeeper and comparative ΔCq) and developed a new 3-way linear mixed-effects model for evaluation of reference gene stability. This new technique utilises the intra-class correlation coefficient as the stability measure for multiple continuous and categorical covariates when determining the optimum normalisation factor. The model also determines confidence intervals for each candidate normalisation gene to facilitate selection and allow sample size calculation for designing experiments to identify reference genes. Of the 10 candidate reference genes tested, the geometric mean of polyadenylate-binding nuclear protein 1 (PABPN1) and beta-actin (ACTB) was the most stable reference combination. In contrast, commonly used ribosomal 18S and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were the most unstable. We compared the use of PABPN1×ACTB and 2 commonly used genes 18S and GAPDH on the expression of 4 genes of interest know to vary after renal injury and expressed by different kidney cell types (KIM-1, HIF1α, TGFβ1 and PECAM1). The less stable reference genes gave varying patterns of GOI expression in contrast to the use of the least unstable reference PABPN1×ACTB combination; this improved detection of differences in gene expression between experimental groups. Reduced within-group variation of the now more accurately normalised GOI may allow for reduced experimental group size particularly for comparison between various models. This objective selection of stable reference genes increased the reliability of comparisons within and between experimental groups.


  • Advances in Detection of Kidney Transplant Injury

    by Sanjeeva Herath, Jonathan Erlich, Amy Y. M. Au, Zoltán H. Endre

    Early detection of graft injury after kidney transplantation is key to maintaining long-term good graft function. Graft injury could be due to a multitude of factors including ischaemia reperfusion injury, cell or antibody-mediated rejection, progressive interstitial fibrosis and tubular atrophy, infections and toxicity from the immunosuppressive drugs themselves. The current gold standard for assessing renal graft dysfunction is renal biopsy. However, biopsy is usually late when triggered by a change in serum creatinine and of limited utility in diagnosis of early injury when histological changes are equivocal. Therefore, there is a need for timely, objective and non-invasive diagnostic techniques with good early predictive value to determine graft injury and provide precision in titrating immunosuppression. We review potential novel plasma and urine biomarkers that offer sensitive new strategies for early detection and provide major insights into mechanisms of graft injury. This is a rapidly expanding field, but it is likely that a combination of biomarkers will be required to provide adequate sensitivity and specificity for detecting graft injury.